Fernández-Vega Ophthalmological Institute, Surgery Department, School of Medicine, University of Oviedo, Oviedo, Spain.
J Cataract Refract Surg. 2010 Jun;36(6):906-16. doi: 10.1016/j.jcrs.2009.11.032.
To assess the safety, efficacy, stability, and predictability of collagen copolymer toric phakic intraocular lens (pIOL) implantation to correct myopia and astigmatism in eyes with keratoconus.
Fernández-Vega Ophthalmological Institute, Oviedo, Spain.
This prospective study comprised keratoconic eyes that had implantation of a toric Intraocular Collamer Lens. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, and postoperative complications were evaluated 1, 3, 6, and 12 months postoperatively.
Preoperatively, the mean spherical equivalent in the 30 eyes (21 patients) was -5.38 diopters (D) +/- 3.26 (SD) (range -13.50 to -0.63 D) and the mean cylinder, -3.48 +/- 1.24 D (range -1.75 to -6.00 D). At 12 months, 86.7% of the eyes were within +/-0.50 D of the attempted refraction and all eyes were within +/-1.00 D. For the astigmatic components J0 and J45, 83.3% of eyes and 86.7% of eyes, respectively, were within +/-0.50 D. The mean Snellen UDVA was 0.81 +/- 0.20 and the mean CDVA, 0.83 +/- 0.18; CDVA was 20/40 or better in 29 eyes 96.7% of eyes and 20/25 or better in 22 eyes (73.3%). No eyes lost more than 2 lines of CDVA; 29 eyes (96.7%) maintained or gained 1 or more lines. The efficacy index was 1.07 and the safety index, 1.16. There were no complications or adverse events.
The results confirm that toric ICL implantation is a predictable, effective procedure to correct ametropia in eyes with keratoconus. Predictability and stability were achieved early and remained fairly stable up to 12 months.
评估胶原共聚物散光型有晶状体眼人工晶状体(pIOL)植入术矫正圆锥角膜患者近视和散光的安全性、有效性、稳定性和可预测性。
西班牙奥维耶多费尔南德斯-维加眼科研究所。
这项前瞻性研究包括植入散光型人工晶状体科尔玛的圆锥角膜眼。术后 1、3、6 和 12 个月评估未矫正(UDVA)和矫正(CDVA)远视力、屈光度和术后并发症。
术前 30 只眼(21 例)平均等效球镜为-5.38 屈光度(D)+/-3.26(SD)(范围-13.50 至-0.63 D),平均柱镜为-3.48 +/- 1.24 D(范围-1.75 至-6.00 D)。12 个月时,86.7%的眼屈光度在-0.50 D 的目标值以内,所有眼均在-1.00 D 以内。对于 J0 和 J45 散光分量,分别有 83.3%和 86.7%的眼在-0.50 D 的目标值以内。平均 Snellen UDVA 为 0.81 +/- 0.20,平均 CDVA 为 0.83 +/- 0.18;29 只眼(96.7%)的 CDVA 为 20/40 或更好,22 只眼(73.3%)的 CDVA 为 20/25 或更好。没有眼睛失去超过 2 行 CDVA;29 只眼(96.7%)保持或增加了 1 行或更多行。疗效指数为 1.07,安全性指数为 1.16。没有并发症或不良事件。
结果证实,散光 ICL 植入术是一种可预测的、有效的矫正圆锥角膜患者屈光不正的方法。可预测性和稳定性在早期实现,并在 12 个月内保持相对稳定。